These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 37258034)

  • 1. Evaluation of integrase resistance in individuals who failed a regimen containing dolutegravir in French and Italian clinical settings.
    Armenia D; Santoro MM; Charpentier C; Bertoli A; Forbici F; Calvez V; Descamps D; Ceccherini-Silberstein F; Marcelin AG; Flandre P
    J Antimicrob Chemother; 2023 Jun; 78(6):1415-1422. PubMed ID: 37258034
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevalence and determinants of resistance mutations in HIV-1-infected patients exposed to integrase inhibitors in a large Italian cohort.
    Modica S; Rossetti B; Lombardi F; Lagi F; Maffeo M; D'Autilia R; Pecorari M; Vicenti I; Bruzzone B; Magnani G; Paolucci S; Francisci D; Penco G; Sacchini D; Zazzi M; De Luca A; Di Biagio A
    HIV Med; 2019 Feb; 20(2):137-146. PubMed ID: 30461149
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Integrase strand transfer inhibitor (INSTI)-resistance mutations for the surveillance of transmitted HIV-1 drug resistance.
    Tzou PL; Rhee SY; Descamps D; Clutter DS; Hare B; Mor O; Grude M; Parkin N; Jordan MR; Bertagnolio S; Schapiro JM; Harrigan PR; Geretti AM; Marcelin AG; Shafer RW;
    J Antimicrob Chemother; 2020 Jan; 75(1):170-182. PubMed ID: 31617907
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of HIV-1 integrase resistance emergence and evolution in patients treated with integrase inhibitors.
    Scutari R; Alteri C; Vicenti I; Di Carlo D; Zuccaro V; Incardona F; Borghi V; Bezenchek A; Andreoni M; Antinori A; Perno CF; Cascio A; De Luca A; Zazzi M; Santoro MM;
    J Glob Antimicrob Resist; 2020 Mar; 20():163-169. PubMed ID: 31330378
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Susceptibility to HIV-1 integrase strand transfer inhibitors (INSTIs) in highly treatment-experienced patients who failed an INSTI-based regimen.
    Santoro MM; Fornabaio C; Malena M; Galli L; Poli A; Menozzi M; Zazzi M; White KL; Castagna A;
    Int J Antimicrob Agents; 2020 Jul; 56(1):106027. PubMed ID: 32450199
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of combinations of clinically observed HIV integrase mutations on phenotypic resistance to integrase strand transfer inhibitors (INSTIs): a molecular study.
    Cheung PK; Shahid A; Dong W; Lepik KJ; Montaner JSG; Brockman MA; Brumme ZL; Brumme CJ
    J Antimicrob Chemother; 2022 Mar; 77(4):979-988. PubMed ID: 35061879
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A systematic review of the genetic mechanisms of dolutegravir resistance.
    Rhee SY; Grant PM; Tzou PL; Barrow G; Harrigan PR; Ioannidis JPA; Shafer RW
    J Antimicrob Chemother; 2019 Nov; 74(11):3135-3149. PubMed ID: 31280314
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Accumulation of integrase strand transfer inhibitor resistance mutations confers high-level resistance to dolutegravir in non-B subtype HIV-1 strains from patients failing raltegravir in Uganda.
    Ndashimye E; Avino M; Olabode AS; Poon AFY; Gibson RM; Li Y; Meadows A; Tan C; Reyes PS; Kityo CM; Kyeyune F; Nankya I; Quiñones-Mateu ME; Arts EJ
    J Antimicrob Chemother; 2020 Dec; 75(12):3525-3533. PubMed ID: 32853364
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Integrase Strand Transfer Inhibitor (INSTI) Genotypic Resistance Analysis in Treatment-Naive, INSTI Free Antiretroviral-Experienced and INSTI-Experienced Turkish Patients Infected with HIV-1.
    Sayan M; Yildirim FS; Akhan S; Karaoglan I; Akalin H
    Curr HIV Res; 2022 Aug; 20(2):184-192. PubMed ID: 35240975
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term efficacy of dolutegravir in treatment-experienced subjects failing therapy with HIV-1 integrase strand inhibitor-resistant virus.
    Castagna A; Ferrara M; Galli L; Comi L; Sterrantino G; Cenderello G; Zaccarelli M; Focà E; Roncadori A; Lazzarin A;
    J Antimicrob Chemother; 2018 Jan; 73(1):177-182. PubMed ID: 29077927
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Natural polymorphism S119R of HIV-1 integrase enhances primary INSTI resistance.
    Hachiya A; Ode H; Matsuda M; Kito Y; Shigemi U; Matsuoka K; Imamura J; Yokomaku Y; Iwatani Y; Sugiura W
    Antiviral Res; 2015 Jul; 119():84-8. PubMed ID: 25956162
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emergence of Resistance in HIV-1 Integrase with Dolutegravir Treatment in a Pediatric Population from the IMPAACT P1093 Study.
    Vavro C; Ruel T; Wiznia A; Montañez N; Nangle K; Horton J; Buchanan AM; Stewart EL; Palumbo P
    Antimicrob Agents Chemother; 2022 Jan; 66(1):e0164521. PubMed ID: 34694878
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Resistance to HIV integrase strand transfer inhibitors in Argentina: first interim survey.
    Cecchini DM; Castillo S; Copertari G; Lacal V; Rodriguez CG; Cassetti I
    Rev Esp Quimioter; 2019 Jun; 32(3):263-267. PubMed ID: 31037930
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment Emergent Dolutegravir Resistance Mutations in Individuals Naïve to HIV-1 Integrase Inhibitors: A Rapid Scoping Review.
    Tao K; Rhee SY; Chu C; Avalos A; Ahluwalia AK; Gupta RK; Jordan MR; Shafer RW
    Viruses; 2023 Sep; 15(9):. PubMed ID: 37766338
    [No Abstract]   [Full Text] [Related]  

  • 15. Antiviral activity of HIV-1 integrase strand-transfer inhibitors against mutants with integrase resistance-associated mutations and their frequency in treatment-naïve individuals.
    Margot NA; Ram RR; White KL; Abram ME; Callebaut C
    J Med Virol; 2019 Dec; 91(12):2188-2194. PubMed ID: 31389026
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factors associated with the emergence of integrase resistance mutations in patients failing dual or triple integrase inhibitor-based regimens in a French national survey.
    Marcelin AG; Charpentier C; Bellecave P; Abdi B; Chaix ML; Ferre V; Raymond S; Fofana D; Bocket L; Mirand A; Le Guillou-Guillemette H; Montes B; Amiel C; Pallier C; Fafi-Kremer S; De Monte A; Alessandri-Gradt E; Scholtes C; Maillard A; Jeulin H; Bouvier-Alias M; Roussel C; Dos Santos G; Signori-Schmuck A; Dina J; Vallet S; Stefic K; Soulié C; Calvez V; Descamps D; Flandre P;
    J Antimicrob Chemother; 2021 Aug; 76(9):2400-2406. PubMed ID: 34100068
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Integrase Inhibitor Resistance Mechanisms and Structural Characteristics in Antiretroviral Therapy-Experienced, Integrase Inhibitor-Naive Adults with HIV-1 Infection Treated with Dolutegravir plus Two Nucleoside Reverse Transcriptase Inhibitors in the DAWNING Study.
    Underwood M; Horton J; Nangle K; Hopking J; Smith K; Aboud M; Wynne B; Sievers J; Stewart EL; Wang R
    Antimicrob Agents Chemother; 2022 Jan; 66(1):e0164321. PubMed ID: 34694877
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pre-Treatment Integrase Inhibitor Resistance and Natural Polymorphisms among HIV-1 Subtype C Infected Patients in Ethiopia.
    Arimide DA; Szojka ZI; Zealiyas K; Gebreegziabxier A; Adugna F; Sasinovich S; Björkman P; Medstrand P
    Viruses; 2022 Mar; 14(4):. PubMed ID: 35458459
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A clinical review of HIV integrase strand transfer inhibitors (INSTIs) for the prevention and treatment of HIV-1 infection.
    Zhao AV; Crutchley RD; Guduru RC; Ton K; Lam T; Min AC
    Retrovirology; 2022 Oct; 19(1):22. PubMed ID: 36273165
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Resistance to integrase inhibitors: a national study in HIV-1-infected treatment-naive and -experienced patients.
    Marcelin AG; Grude M; Charpentier C; Bellecave P; Le Guen L; Pallier C; Raymond S; Mirand A; Bocket L; Fofana DB; Delaugerre C; Nguyen T; Montès B; Jeulin H; Mourez T; Fafi-Kremer S; Amiel C; Roussel C; Dina J; Trabaud MA; Le Guillou-Guillemette H; Vallet S; Signori-Schmuck A; Maillard A; Ferre V; Descamps D; Calvez V; Flandre P;
    J Antimicrob Chemother; 2019 May; 74(5):1368-1375. PubMed ID: 30789205
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.